Significant contract signed to manufacture lateral flow device components
Abingdon Health PLC (AIM:ABDX) Significant contract to manufacture LFD components
Abingdon Health PLC (AIM:ABDX) Strategic collaboration with Bimelix Ab
Focused on the on development and commercialisation of Lyme disease lateral flow self-test
Abingdon Health PLC (AIM:ABDX) Completion of Technical Transfer & initial orders
Completion of Technical Transfer to full-scale manufacture and initial orders for Vatic KnowNowTM test
Genedrive PLC (AIM:GDR) NICE issues Medtech Innovation Briefing
NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test
Genedrive® MT-RNR1 ID Kit Product – Video
World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss
Genedrive PLC (AIM:GDR) First NHS Deployments of Genedrive System for AIHL
First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss
Genedrive PLC (AIM: GDR) Update on Point of Care Covid Test
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, provides an update on the progress being made on the Genedrive®COV19-ID kit, its rapid point of care molecular test for
Genedrive PLC (GDR.L) Investor Presentation
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2021 on Tuesday, 29 March 2022.
Abingdon Health PLC (ABDX.L) Update on AffiDX® SARS-CoV-2 antigen LFT
Technical transfer completed mid-December as planned
Genedrive PLC (GDR.L) UK CTDA application for Genedrive® COV19-ID kit
Sensitivity and specificity data submitted meets MHRA requirements
Genedrive PLC (GDR.L) CE-IVD certification for Point-of-Care Genedrive®COV19-ID kit
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to the announcement of 29 November 2021, its rapid point of care Genedrive®COV19-ID Kit has received CE-IVD
